Prostate Cell News 10.31 August 23, 2019 | |
| |
TOP STORYThe Δ133p53β Isoform Promotes an Immunosuppressive Environment Leading to Aggressive Prostate Cancer RNA-seq of tumors showed enrichment for pathways associated with immune signaling and cell migration. Sceintists showed a role for hypoxia and wild-type p53 in upregulating Δ133TP53 levels. [Cell Death Dis] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Fluorescence microscopy demonstrated that androgen promoted the nucleus translocation of androgen receptor (AR) in prostate cancer cells, while treatment with caffeic acid phenethyl ester reduced protein level of AR in both the nucleus and cytoplasm. [Cell Commun Signal] Full Article | Graphical Abstract Membrane-initiated estrogen signaling was interrogated in human prostate stem-progenitor cells enriched from primary epithelial cultures and stem-like cell lines from benign and cancerous prostates. [Endocrinology] Abstract The Role of WNT10B in Normal Prostate Gland Development and Prostate Cancer WNT10B mRNA levels were increased in the metastatic cell lines PC3, PC3M, as well as in HuSLC, a prostate cancer stem‐like cell line, as compared with disease‐free primary prostate epithelial cells. [Prostate] Abstract Scientists indicated that ouabain induced cell morphological changes, decreased total cell viability, induced G0/G1 phase arrest, DNA damage, and cell apoptosis, increased ROS and Ca2+ production, but decreased the levels of ΔΨm in DU 145 cells. [Environ Toxicol] Abstract A Molecule Inducing Androgen Receptor Degradation and Selectively Targeting Prostate Cancer Cells Ex vivo, IRC117539-mediated androgen receptor (AR) degradation induced prostate cancer cell viability loss by inhibiting AR signaling, even in androgen-insensitive cells. [Life Sci Alliance] Full Article Cytotoxicity of xanthoquinodin was evaluated in a panel of human cancer cells lines and CCD-112-CoN normal colon cells, using the sulforhodamine B assay. PC-3 prostate cancer cells were used in biochemical assays including cell cycle, mitochondrial transmembrane potential, reactive oxygen species and caspase activity. [Chem Biol Interact] Abstract | Graphical Abstract JAB1/COPS5 Is a Putative Oncogene that Controls Critical Oncoproteins Deregulated in Prostate Cancer To test the function of c-Jun activation domain-binding protein 1 (JAB1) in prostate cancer (PCa), the authors efficiently silenced JAB1 expression using four unique shRNAs in three PCa cell lines and an immortalized prostate epithelial cell line, RWPE-1. [Biochem Biophys Res Commun] Abstract Black raspberry extract, the anthocyanin cyanidin-3-rutinoside and protocatechuic acid did not inhibit prostate cancer cell growth in vitro, but ellagic acid and its urolithin A metabolite did at high concentrations. [Nutr Cancer] Abstract Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News. | |
| |
REVIEWSMain Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer Various immune cells including tumor-associated neutrophils, tumor-infiltrating macrophages, myeloid-derived suppressor cells, and mast cells promote prostate cancer via various intercellular signaling. Further basic studies examining the relationship between the inflammatory process and prostate cancer progression are warranted. [Cancers] Full Article Visit our reviews page to see a complete list of reviews in the prostate cell research field. | |
| |
INDUSTRY NEWSAstellas Pharma Inc. and Pfizer Inc. announced that the FDA has accepted for review the filing of a supplemental New Drug Application for XTANDI® to add an indication for the treatment of men with metastatic hormone-sensitive prostate cancer. [Astellas Pharma Inc.] Press Release Calibr announced that the FDA has cleared its investigational new drug application (IND) for CCW702, a novel immunotherapeutic for the treatment of patients with metastatic castration-resistant prostate cancer. [Scripps Research] Press Release | |
| |
POLICY NEWSMore Than 700 German Research Institutions Strike Open-Access Deal with Springer Nature A consortium of more than 700 German research institutions and libraries announced an agreement with publisher Springer Nature to make it simpler for authors to publish their papers open access. The agreement is the largest national open-access deal to date, but it doesn’t allow authors to publish open access in Nature or its sister journals. [ScienceInsider] Editorial As Brexit Nears, Britain’s Drugs, Devices and Pricing Regulators Seek the Exit Firm details on exactly how the UK will regulate new medicines is still to be decided after it leaves the EU later this year, but we now know that the regulator won’t be run by Dr. Ian Hudson, who is stepping down after six years in charge. [FierceBiotech] Editorial
| |
EVENTSNEW Cancer Epigenetics: New Mechanisms and Therapeutic Opportunities Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESScientific Communications Coordinator (STEMCELL Technologies Inc.) Senior Research Assistant – Genitourinary Oncology (MD Anderson Cancer Center) Postdoctoral Position – Prostate Cancer (Roswell Park Comprehensive Cancer Center) Postdoctoral Scientist – Prostate Oncobiology (Cancer Research UK) Research Officer – Tumor Progression (Garvan Institute of Medical Research) Postdoctoral Researcher – Genitourinary Cancers (Columbia University) Senior Endowed Professorship – Cellular Principles & Evolution (Stony Brook University) Postdoctoral Position – Prostate Biology (University of Washington) Postdoctoral Scientist – Prostate Organoids (Rutgers Cancer Institute of New Jersey) Research Lab Specialist – Tumor Microenvironment & Cell Behavior (University of Southern California) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Prostate Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|